Mesoblast acquires Angioblast to bring adult stem cell platform under one roof
This article was originally published in Scrip
Executive Summary
Mesoblast of Australia is to acquire the remaining 67% stake in the privately held US firm Angioblast Systems that it does not already own, bringing commercial rights to an adult stem cell technology platform that both companies are working on under one umbrella.